Cover Image
市場調查報告書

SBI Biotech Co., Ltd. : 產品平台分析

SBI Biotech Co., Ltd. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 199795
出版日期 內容資訊 英文 23 Pages
訂單完成後即時交付
價格
Back to Top
SBI Biotech Co., Ltd. : 產品平台分析 SBI Biotech Co., Ltd. - Product Pipeline Review - 2015
出版日期: 2015年10月30日 內容資訊: 英文 23 Pages
簡介

SBI Biotech Co., Ltd. 是以生命科學為基礎的生物創投公司,致力於免疫細胞治療用藥物,及癌症和B細胞慢性淋巴性白血病,自體免疫疾病,以及過敏治療用機能性食品的研究·開發。

本報告提供SBI Biotech Co., Ltd.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

SBI Biotech Co., Ltd.的基本資料

  • SBI Biotech Co., Ltd.概要
  • 主要資訊
  • 企業資料

SBI Biotech Co., Ltd.:R&D概要

  • 主要的治療範圍

SBI Biotech Co., Ltd.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

SBI Biotech Co., Ltd.:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

SBI Biotech Co., Ltd.:藥物簡介

  • GNKS-356
  • SBI-3150
  • SBI-9674
  • Small Molecule to Inhibit Cdc7/ASK for Oncology

SBI Biotech Co., Ltd.:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

SBI Biotech Co., Ltd.:暫停中的計劃

SBI Biotech Co., Ltd.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • GNKG-168

SBI Biotech Co., Ltd.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07722CDB

Summary

Global Markets Direct's, 'SBI Biotech Co., Ltd. - Product Pipeline Review - 2015', provides an overview of the SBI Biotech Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of SBI Biotech Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of SBI Biotech Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of SBI Biotech Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the SBI Biotech Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate SBI Biotech Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of SBI Biotech Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the SBI Biotech Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of SBI Biotech Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of SBI Biotech Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of SBI Biotech Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • SBI Biotech Co., Ltd. Snapshot
    • SBI Biotech Co., Ltd. Overview
    • Key Information
    • Key Facts
  • SBI Biotech Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • SBI Biotech Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • SBI Biotech Co., Ltd. - Pipeline Products Glance
    • SBI Biotech Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • SBI Biotech Co., Ltd. - Drug Profiles
    • GNKS-356
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SBI-3150
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SBI-9674
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Cdc7/ASK for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • SBI Biotech Co., Ltd. - Pipeline Analysis
  • SBI Biotech Co., Ltd. - Pipeline Products by Target
  • SBI Biotech Co., Ltd. - Pipeline Products by Molecule Type
  • SBI Biotech Co., Ltd. - Pipeline Products by Mechanism of Action
  • SBI Biotech Co., Ltd. - Dormant Projects
  • SBI Biotech Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • GNKG-168
  • SBI Biotech Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • SBI Biotech Co., Ltd., Key Information
  • SBI Biotech Co., Ltd., Key Facts
  • SBI Biotech Co., Ltd. - Pipeline by Indication, 2015
  • SBI Biotech Co., Ltd. - Pipeline by Stage of Development, 2015
  • SBI Biotech Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • SBI Biotech Co., Ltd. - Out-Licensed Products in Pipeline, 2015
  • SBI Biotech Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • SBI Biotech Co., Ltd. - Preclinical, 2015
  • SBI Biotech Co., Ltd. - Pipeline by Target, 2015
  • SBI Biotech Co., Ltd. - Pipeline by Molecule Type, 2015
  • SBI Biotech Co., Ltd. - Pipeline Products by Mechanism of Action, 2015
  • SBI Biotech Co., Ltd. - Dormant Developmental Projects,2015
  • SBI Biotech Co., Ltd. - Discontinued Pipeline Products, 2015
  • SBI Biotech Co., Ltd., Subsidiaries

List of Figures

  • SBI Biotech Co., Ltd. - Pipeline by Top 10 Indication, 2015
  • SBI Biotech Co., Ltd. - Pipeline by Top 10 Target, 2015
  • SBI Biotech Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • SBI Biotech Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top